Company profile
LENZ THERAPEUTICS, INC.
NASDAQ:LENZBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VIZZ | approved | $5.0MQ2 2025 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03201562 | phase2 | completed | 2017-04-30 | 2018-05-20 | LENZ Therapeutics, Inc | A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia |
| NCT02554396 | phase2 | completed | 2015-09-01 | 2015-11-01 | LENZ Therapeutics, Inc | Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia |
| NCT05431543 | phase2 | completed | 2022-08-06 | 2022-12-14 | LENZ Therapeutics, Inc | Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia |
| NCT05294328 | phase2 | completed | 2022-05-05 | 2022-08-22 | LENZ Therapeutics, Inc | Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia |
| NCT05728944 | phase3 | completed | 2023-03-06 | 2023-12-14 | LENZ Therapeutics, Inc | Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 218585 | 2025-07-31 | NDA | LENZ THERAPEUTICS INC | |||||
Loading… | ||||||||